BMRN Form 144: Fidelity proposes sale of common stock

BioMarin Pharmaceutical (BMRN) filed a Form 144 reporting a proposed sale of common stock by Fidelity Brokerage Services LLC.

Rhea-AI Filing Summary

BioMarin Pharmaceutical (BMRN) filed a Form 144 reporting a proposed sale of common stock by Fidelity Brokerage Services LLC. The notice lists multiple lots tied to prior acquisitions, including 1,474 shares from a stock option exercise (02/24/2023), 317 shares from an ESPP purchase (04/30/2023), 301 shares from an ESPP purchase (04/30/2024), and 23,969 shares from restricted stock vesting (03/15/2025).

Insights

Insider Transactions Specialist

Form 144 lists proposed reseller lots tied to prior grants and purchases.

The notice names Fidelity Brokerage Services LLC as the broker and itemizes lots by acquisition type and date, including option exercise, ESPP purchases, and restricted stock vesting. Each lot is presented as a discrete quantity of common shares.

Timing and actual sale execution are not stated here; subsequent filings or broker reports would show whether and when these lots were sold.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BMRN Form 144 filed by Fidelity mean?

It notifies the SEC of a proposed sale of BioMarin common stock by Fidelity Brokerage Services LLC. The filing lists specific lots by acquisition type and date, indicating intent to sell shares previously acquired via options, ESPP purchases, and vesting.

How many BMRN shares does the Form 144 list for possible sale?

The notice itemizes multiple lots: 1,474; 317; 301; and 23,969 shares. Each number is tied to a specific acquisition event and date shown in the filing, presented as separate lots rather than an aggregated total.

Who is the broker or intermediary named on the Form 144 for BMRN?

The filing lists Fidelity Brokerage Services LLC with an address in Smithfield, RI as the broker associated with the proposed sale. No purchaser or sale execution details are provided in this excerpt.

Do the listed acquisition dates on the Form 144 affect how the sale is treated?

The filing ties each lot to its acquisition date—02/24/2023, 04/30/2023, 04/30/2024, and 03/15/2025—showing when the shares were acquired through exercise, ESPP purchases, or vesting. The filing does not state sale dates or methods.

Does this Form 144 confirm the shares have been sold?

No. Form 144 is a notice of a proposed sale and lists intended lots; it does not confirm execution. Subsequent transaction reports or broker records would be required to confirm actual sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 10:18 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001380710
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BIOMARIN PHARMACEUTICAL INC
SEC File Number	000-26727
Address of Issuer	105 DIGITAL DRIVE NOVATO CALIFORNIA 94949
Phone	4155066700
Name of Person for Whose Account the Securities are To Be Sold	Davis George Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	26061	1599102.96	192114344	02/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/24/2023	Stock Option Exercise	Issuer			1474	02/24/2023	Cash
Common	04/30/2023	ESPP Purchase	Issuer			317	04/30/2023	Cash
Common	04/30/2024	ESPP Purchase	Issuer			301	04/30/2024	Cash
Common	03/15/2025	Restricted Stock Vesting	Issuer			23969	03/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Emily Navaro, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for George E. Davis.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)